Robins Kaplan Named “Recommended Firm” for Hatch-Waxman Litigation; Several Partners “life Sciences Stars”

October 12, 2020

Robins Kaplan LLP is pleased to announce that LMG Life Sciences has recommended the firm as a top Hatch-Waxman patent litigation firm nationwide for generic pharmaceutical companies. In addition, Jake Holdreith, Jeffrey Hovden, Oren Langer, and Ronald Schutz have been named “Life Science Stars.”

  • Jake Holdreith is a member of the firm’s Executive Board. He has tried jury cases to multi-million dollar verdicts and resolved complex cases at all stages of litigation. He is a skilled and creative strategist and business counselor who can cut to the heart of a matter in the boardroom and the courtroom. Holdreith is known for work in in the pharmaceutical, chemical, and electronics industries and has handled cases in the United States, Europe, and Asia.
  • Oren Langer’s intellectual property litigation experience spans various industries including pharmaceuticals (under the Hatch-Waxman regulatory framework), chemicals, telecommunications, video gaming, retail services, and representing clients in Rate Court proceedings. Prior to his legal career, Mr. Langer earned a Bachelor's degree in chemistry and interned and worked at Bristol-Myers Squibb and Pharmacopeia as an organic chemist.
  • Ronald Schutz is chair of the firm’s Executive Board. He is a fellow of the American College of Trial Lawyers and has been recognized by many legal organizations and publications as one of the top lawyers in the country, including The National Law Journal, which named him one of the “Top 10 Winning Litigators in the United States.” He has won a nine-figure and multiple eight-figure jury verdicts, and has secured victories against behemoths such as Apple, Clear Channel, Sony, and Canon. 

Jake M. Holdreith


Member of Executive Board

Oren D. Langer


Managing Partner, New York Office

Ronald J. Schutz


Chair of Executive Board

Related Publications

Fourth Quarter
Generically Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Bernard Pound
Fourth Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
December 27, 2022
Takeda Pharm. Co. Ltd. v. Norwich Pharms., Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 22, 2022
Genentech, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2022
Vanda Pharms., Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top